Develops personalized cytokine-based therapies using a proprietary Diakine™ platform that combines anti-inflammatory and immune-stimulating cytokines to target cancer and inflammatory diseases. This approach enriches affected tissues with tailored cytokine combinations, aiming to control disease while minimizing toxic inflammation, offering a precision medicine solution for individual patient immune responses.
Funding
$90.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer and inflammatory disease treatments often fail to elicit a sufficient or targeted immune response, leading to limited efficacy and systemic toxicities. Existing immunotherapies may not effectively penetrate affected tissues or modulate the immune system in a manner tailored to individual patient needs.
Solution
Deka Biosciences is developing personalized cytokine-based therapies using its proprietary Diakine™ platform to address these limitations. The Diakine™ platform combines anti-inflammatory and immune-stimulating cytokines into a single molecule, enabling targeted delivery and precise modulation of the immune response within affected tissues. By enriching the local microenvironment with tailored cytokine combinations, Diakine™ therapies aim to enhance disease control while minimizing systemic inflammation and toxicity. This approach allows for the development of precision medicine solutions that are tailored to individual patient immune responses in both cancer and inflammatory diseases.
Target Audience
The primary target audience includes patients with cancer and inflammatory diseases, as well as clinicians and researchers seeking more effective and targeted immunotherapies.
Features
- Diakine™ platform enables the combination of two anti-inflammatory cytokines for inflammatory diseases.
- Diakine™ platform enables the combination of an immune-stimulating cytokine and an anti-inflammatory cytokine for cancer.
- scFv scaffold directs Diakine™ to the tumor microenvironment or inflamed tissue.
- Targets MAdCAM for Crohn’s and colitis, VEGFR2 for Psoriasis and Rheumatoid Arthritis, or CD14 for sepsis.
- Targets EGFR, HER2, and VEGFR receptors on tumor cells.
- Protein subunits are linked in series via flexible protein linkers, creating a stable, antibody-like structure.
- Interleukin-10 (IL-10) is used as a potent anti-inflammatory cytokine to control toxic inflammation.